Gene therapy for leukodystrophies.

  title={Gene therapy for leukodystrophies.},
  author={Alessandra Biffi and Patrick R. Aubourg and Nathalie Cartier},
  journal={Human molecular genetics},
  volume={20 R1},
Leukodystrophies (LDs) refer to a group on inherited diseases in which molecular abnormalities of glial cells are responsible for exclusive or predominant defects in myelin formation and/or maintenance within the central and, sometimes, the peripheral nervous system. For three of them [X-linked adrenoleukodystrophy (X-ALD), metachromatic (MLD) and globoid cell LDs], a gene therapy strategy aiming at transferring the disease gene into autologous hematopoietic stem cells (HSCs) using lentiviral… 

Figures from this paper

Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy

The reconstitution of ARSA activity in the cerebrospinal fluid and the arrested progression of neurodegenerative disease in the three treated patients demonstrate that the transplanted cells, or their progeny, can seed the nervous system and deliver therapeutic levels of active enzyme.

Emerging Concepts in Vector Development for Glial Gene Therapy: Implications for Leukodystrophies

This work links recent advances in vectorology to glial targeting directed towards gene therapies for specific leukodystrophies and related developmental or neurometabolic disorders affecting the CNS white matter and frame strategies for therapy development in future.

Evaluating experimental treatment of leukodystrophies

Clinical deterioration over time in patients with different types of metachromatic leukodystrophy is described in quantitative terms, representing a solid framework of data that can be used in present and future therapies to detect modifications of the natural course.

Metachromatic leukodystrophy: Disease spectrum and approaches for treatment.

Gene Therapy for Nonmalignant Hematology

  • Xiuyan WangI. Rivière
  • Biology, Medicine
    Advances and Controversies in Hematopoietic Transplantation and Cell Therapy
  • 2018
The discovery and maturation of gene-editing platforms, including zinc-finger nuclease (ZFN), transcription activator-like effector nucleases (TALEN), and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9, offer exciting prospective strategies for further improving gene therapy by targeting the repair of diseased genes.

Perspective on innovative therapies for globoid cell leukodystrophy

Evidence is evaluated from extensive experimental studies on GLD animal models that have highlighted fundamental requirements to obtain substantial therapeutic benefit, including early and timely intervention, high levels of enzymatic reconstitution, and global targeting of affected tissues.

Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy

A focused literature review was performed using the terms ‘hematopoietic stem cell transplantation,’ ‘gene therapy’ and ‘adrenoleukodystrophy’ to include relevant literature, especially comparing the experience with gene therapy and HSCT outcomes, to review the history and experience with HSCT in cerebral ALD.

Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy

It is demonstrated here that neonatal lentiviral vector-mediated intracerebral gene therapy (IC GT) or transplantation of GALC-overexpressing neural stem cells (NSC) synergize with bone marrow transplant (BMT) providing dramatic extension of lifespan and global clinical–pathological rescue in a relevant GLD murine model.

Gene-based approaches to inherited neurometabolic diseases.

An overview of the gene therapy strategies currently under clinical investigation for neurometabolic Lysosomal and Peroxisomal Storage Diseases such as Adreno and Metachromatic Leukodystrophies, as well as novel emerging indications as Mucopolysaccharidoses, Gangliosidoses and Neuronal Ceroid Lipofuscinoses are provided.



Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice.

Results indicate that the recruitment of gene-modified, enzyme-overexpressing microglia makes the enzyme bioavailable to the brain and makes therapeutic efficacy and disease correction attainable.

Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy

Lentiviral-mediated gene therapy of hematopoietic stem cells can provide clinical benefits in ALD, and progressive cerebral demyelination in the two patients stopped, a clinical outcome comparable to that achieved by allogeneic HCT.

Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells.

Ex vivo gene therapy had a significantly higher therapeutic impact than WT HSC transplantation, indicating a critical role for enzyme overexpression in the HSC progeny and indicates that transplantation of LV-transduced autologous HSCs represents a potentially efficacious therapeutic strategy for MLD and possibly other neurodegenerative disorders.

Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy.

Data indicate that from the perspective of clinical translation, therapeutic levels of ARSA overexpression can be safely achieved and demonstrate an experimental platform for the preclinical assessment of the safety of new gene therapy approaches.

Krabbe disease: genetic aspects and progress toward therapy.

Treatment ofrabbe disease or globoid cell leukodystrophy is limited to hematopoietic stem cell transplantation that appears to slow the progression of the disease and improve the magnetic resonance images.

Globoid Cell Leukodystrophy (Krabbe's Disease): Update

The classic globoid cell leukodystrophy (Krabbe's disease) is caused by genetic defects in a lysosomal enzyme, galactosylceramidase, and a normally insignificant but highly cytotoxic metabolite, galactsylsphingosine (psychosine), is considered to play a critical role in the pathogenesis.

Partial cure of established disease in an animal model of metachromatic leukodystrophy after intracerebral adeno-associated virus-mediated gene transfer

It is shown that adeno-associated virus serotype 5-mediated gene transfer in the brain of ARSA knockout mice reverses Sulf storage and prevents neuropathological abnormalities and neuromotor disabilities when vector injections are performed at a pre-symptomatic stage of disease.

Genes involved in leukodystrophies: A glance at glial functions

Recent advances made in leukodystrophy research are reviewed by identifying causative genes, particularly on the genes involved in the hypomyelinated and vacuolatingLeukodystrophies, which provide new insights into the understanding of myelin formation and WM homeostasis.

Identification of Hematopoietic Stem Cell–Specific miRNAs Enables Gene Therapy of Globoid Cell Leukodystrophy

Hematopoietic stem cell–specific microRNAs allow regulation of therapeutic transgene expression and enable effective gene therapy of globoid cell leukodystrophy and provide a basis for improvements in HSPC-mediated gene therapy and may offer patients a new therapeutic option that resembles a scratch more than a chop.

Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy.

It is believed that AAV5-mediated brain delivery of ARSA is a potentially efficacious therapeutic strategy for MLD patients, especially for those with rapidly progressive form of the disease.